Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Chiron Corp.

(CHIR)

May-Kin Ho of Goldman, Sachs removed Chiron Corp. from the firm's recommended for purchase list and lowered its rating to "moderate

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE